Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.76 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.64 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 8/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479331 | 0.88 | QDPR (0.72) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL16874849 | 0.86 | QDPR (0.66) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL17548153 | 0.86 | QDPR (0.70) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL27553177 | 0.86 | QDPR (0.70) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL10407313 | 0.86 | QDPR (1.00) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| Hydrochloric Acid SCHEMBL979625 | 0.85 | QDPR (0.64) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL24669645 | 0.83 | QDPR (0.66) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL6586294 | 0.83 | QDPR (0.65) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL23730258 | 0.83 | QDPR (0.65) | QDPRTLR9TLR7TGFBR1ACVR1 | |
| SCHEMBL522135 | 0.81 | QDPR (0.62) | QDPRTLR9TLR7TGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| CN-115003665-A | Substituted aminoquinolones as immunoactive DGK alpha inhibitors | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105117-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| US-5410058-A | Exhibit high affinity and specificity to alpha receptors; useful in treating some psychoses | SHIONOGI & CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5362873-A | Tetrahydropyridine derivatives | SHIONOGI & CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| US-5243051-A | Treatment of psychological disorders | SHIONIGI & CO., LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5149817-A | Psychotropic agents | SHIONOGI & CO., LTD. (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0445701-A1 | Novel tetrahydropyridine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | QDPR 186/4885TLR9 553/4885TLR7 256/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | QDPR 186/4885TLR9 553/4885TLR7 256/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | QDPR 186/4885TLR9 553/4885TLR7 256/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | QDPR 186/4885TLR9 553/4885TLR7 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.